DENTSPLY SIRONA (NASDAQ:XRAY) Issues FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.400-1.500 for the period, compared to the consensus EPS estimate of 1.430. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

DENTSPLY SIRONA Stock Down 1.6%

Shares of NASDAQ:XRAY traded down $0.18 during trading on Thursday, reaching $10.96. 6,611,746 shares of the company traded hands, compared to its average volume of 3,887,038. The firm has a fifty day simple moving average of $12.07 and a 200 day simple moving average of $12.00. The company has a quick ratio of 1.03, a current ratio of 1.53 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA has a 1-year low of $9.85 and a 1-year high of $17.18. The firm has a market cap of $2.20 billion, a P/E ratio of -3.48, a price-to-earnings-growth ratio of 1.32 and a beta of 0.93.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The firm had revenue of $880.00 million for the quarter, compared to analyst estimates of $841.80 million. During the same period in the previous year, the business posted $0.43 EPS. DENTSPLY SIRONA’s revenue for the quarter was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts anticipate that DENTSPLY SIRONA will post 1.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on XRAY. Barrington Research boosted their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Citigroup started coverage on shares of DENTSPLY SIRONA in a research note on Wednesday, April 15th. They set a “sell” rating and a $10.00 price target on the stock. Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Robert W. Baird upped their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Finally, Mizuho cut their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $13.82.

Insider Buying and Selling at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director James D. Forbes acquired 5,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were acquired at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the purchase, the director owned 10,000 shares of the company’s stock, valued at approximately $124,800. This trade represents a 100.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Gregory T. Lucier acquired 15,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average cost of $12.45 per share, with a total value of $186,750.00. Following the transaction, the director directly owned 65,000 shares in the company, valued at $809,250. The trade was a 30.00% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 70,000 shares of company stock valued at $956,437. 0.50% of the stock is owned by insiders.

Institutional Investors Weigh In On DENTSPLY SIRONA

Several hedge funds have recently modified their holdings of XRAY. Virtu Financial LLC bought a new position in DENTSPLY SIRONA during the fourth quarter worth $302,000. Compound Planning Inc. acquired a new stake in DENTSPLY SIRONA in the 4th quarter worth $117,000. Invesco Ltd. increased its holdings in shares of DENTSPLY SIRONA by 101.1% during the 4th quarter. Invesco Ltd. now owns 1,063,523 shares of the medical instruments supplier’s stock worth $12,156,000 after purchasing an additional 534,714 shares during the period. Alpine Woods Capital Investors LLC acquired a new position in shares of DENTSPLY SIRONA during the fourth quarter valued at about $680,000. Finally, First Citizens Bank & Trust Co. bought a new stake in shares of DENTSPLY SIRONA in the fourth quarter valued at about $447,000. 95.70% of the stock is owned by institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.